The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158

Detalles Bibliográficos
Autores principales: Mistry, Pramod K., Kishnani, Priya S., Balwani, Manisha, Charrow, Joel M., Hull, Judy, Weinreb, Neal J., Cox, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179580/
https://www.ncbi.nlm.nih.gov/pubmed/37176709
http://dx.doi.org/10.3390/jcm12093269
_version_ 1785041131524849664
author Mistry, Pramod K.
Kishnani, Priya S.
Balwani, Manisha
Charrow, Joel M.
Hull, Judy
Weinreb, Neal J.
Cox, Timothy M.
author_facet Mistry, Pramod K.
Kishnani, Priya S.
Balwani, Manisha
Charrow, Joel M.
Hull, Judy
Weinreb, Neal J.
Cox, Timothy M.
author_sort Mistry, Pramod K.
collection PubMed
description
format Online
Article
Text
id pubmed-10179580
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101795802023-05-13 The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158 Mistry, Pramod K. Kishnani, Priya S. Balwani, Manisha Charrow, Joel M. Hull, Judy Weinreb, Neal J. Cox, Timothy M. J Clin Med Comment MDPI 2023-05-04 /pmc/articles/PMC10179580/ /pubmed/37176709 http://dx.doi.org/10.3390/jcm12093269 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Comment
Mistry, Pramod K.
Kishnani, Priya S.
Balwani, Manisha
Charrow, Joel M.
Hull, Judy
Weinreb, Neal J.
Cox, Timothy M.
The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
title The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
title_full The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
title_fullStr The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
title_full_unstemmed The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
title_short The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
title_sort two substrate reduction therapies for type 1 gaucher disease are not equivalent. comment on hughes et al. switching between enzyme replacement therapies and substrate reduction therapies in patients with gaucher disease: data from the gaucher outcome survey (gos). j. clin. med. 2022, 11, 5158
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179580/
https://www.ncbi.nlm.nih.gov/pubmed/37176709
http://dx.doi.org/10.3390/jcm12093269
work_keys_str_mv AT mistrypramodk thetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT kishnanipriyas thetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT balwanimanisha thetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT charrowjoelm thetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT hulljudy thetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT weinrebnealj thetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT coxtimothym thetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT mistrypramodk twosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT kishnanipriyas twosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT balwanimanisha twosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT charrowjoelm twosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT hulljudy twosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT weinrebnealj twosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158
AT coxtimothym twosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed2022115158

Ejemplares similares